መነሻ › አኩት ማይሎይድ ሊውኬሚያ › Oregon
በOregon ለአኩት ማይሎይድ ሊውኬሚያ የሚደረጉ ክሊኒካዊ ጥናቶች
ለአኩት ማይሎይድ ሊውኬሚያ የሚደረጉ 27 ጥናቶች በOregon ባሉ ቦታዎች ተሳታፊዎችን እየፈለጉ ነው።
በOregon ውስጥ ያሉ ከተሞች
Official study text (English)
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
- Saint Alphonsus Cancer Care Center-Ontario, Ontario
- Providence Portland Medical Center, Portland
- Providence Saint Vincent Medical Center, Portland
ተሳታዮችን በመፈለግ ላይደረጃ 2
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ5 ኦክቶ 2026 · NCT05564390Ruxolitinib With Azacitidine Maintenance for the Treatment of Patients With Acute Myeloid Leukemia Undergoing Reduced Intensity Allogeneic Stem Cell Transplantation
- OHSU Knight Cancer Institute, Portland
ተሳታዮችን በመፈለግ ላይደረጃ 1
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ5 ኦክቶ 2026 · NCT07548983Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Saint Alphonsus Cancer Care Center-Baker City, Baker City
- Saint Charles Health System, Bend
- Clackamas Radiation Oncology Center, Clackamas
- እና 7 ተጨማሪ
ተሳታዮችን በመፈለግ ላይየመመልከት ጥናትጤናማ ተሳታዮች ይቀበላሉ
እድሜ ከ40 እስከ 75 · ሁሉም ጾታዎች · የተሻሻለው በ2 ኦክቶ 2026 · NCT05334069Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
- Saint Alphonsus Cancer Care Center-Ontario, Ontario
- Providence Portland Medical Center, Portland
- Providence Saint Vincent Medical Center, Portland
ተሳታዮችን በመፈለግ ላይደረጃ 2
እድሜ ከ18 እስከ 59 · ሁሉም ጾታዎች · የተሻሻለው በ28 ሴፕቴ 2026 · NCT05554393A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
- Providence Portland Medical Center, Portland
- Providence Oncology and Hematology Care Clinic Westside, Portland
ተሳታዮችን በመፈለግ ላይደረጃ 3
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ25 ሴፕቴ 2026 · NCT06852222Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
- OHSU Knight Cancer Institute, Portland
ተሳታዮችን በመፈለግ ላይደረጃ 1
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ24 ሴፕቴ 2026 · NCT03874052Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
- Saint Alphonsus Cancer Care Center-Ontario, Ontario
- Providence Portland Medical Center, Portland
- Providence Saint Vincent Medical Center, Portland
ተሳታዮችን በመፈለግ ላይደረጃ 2
እድሜ ከ18 እስከ 59 · ሁሉም ጾታዎች · የተሻሻለው በ22 ሴፕቴ 2026 · NCT05554406Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
- Saint Alphonsus Cancer Care Center-Ontario, Ontario
- Providence Portland Medical Center, Portland
- Providence Saint Vincent Medical Center, Portland
ተሳታዮችን በመፈለግ ላይደረጃ 2
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ22 ሴፕቴ 2026 · NCT06317649A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
- Legacy Emanuel Children's Hospital, Portland
- Oregon Health and Science University, Portland
ተሳታዮችን በመፈለግ ላይደረጃ 3
6 Months – 21 Years · ሁሉም ጾታዎች · የተሻሻለው በ17 ሴፕቴ 2026 · NCT04293562Venetoclax in Combination With Cladribine and Cytarabine Alternating With Azacitidine Plus Venetoclax for the Treatment of Newly Diagnosed Monocytic AML and Active Signaling Mutated AML
- OHSU Knight Cancer Institute, Portland
ተሳታዮችን በመፈለግ ላይደረጃ 2
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ16 ሴፕቴ 2026 · NCT06504459A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
- Oregon Health & Science University, Portland
ተሳታዮችን በመፈለግ ላይደረጃ 1/2
30 Days · ሁሉም ጾታዎች · የተሻሻለው በ16 ሴፕቴ 2026 · NCT04065399Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies
- Oregon Health and Science University, Portland
ተሳታዮችን በመፈለግ ላይደረጃ 1/2
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ14 ሴፕቴ 2026 · NCT03471260Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML
- US-Portland OR-OHSU, Portland
ተሳታዮችን በመፈለግ ላይደረጃ 3
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ2 ሴፕቴ 2026 · NCT06652438The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
- Legacy Emanuel Children's Hospital, Portland
- Oregon Health and Science University, Portland
ተሳታዮችን በመፈለግ ላይደረጃ 1/2
እስከ እድሜ 22 · ሁሉም ጾታዎች · የተሻሻለው በ25 ኦገስ 2026 · NCT04726241Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)
- Doernbecher Children's Hospital, Portland
ተሳታዮችን በመፈለግ ላይደረጃ 3
29 Days – 21 Years · ሁሉም ጾታዎች · የተሻሻለው በ24 ኦገስ 2026 · NCT05183035Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
- Willamette Valley Cancer Institute, Eugene
ተሳታዮችን በመፈለግ ላይደረጃ 3
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ20 ኦገስ 2026 · NCT07007312Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT
- Oregon Health & Science University (OHSU) - Knight Cancer Institute, Portland
ተሳታዮችን በመፈለግ ላይደረጃ 3
እድሜ ከ18 እስከ 75 · ሁሉም ጾታዎች · የተሻሻለው በ17 ጁላይ 2026 · NCT05429632Pemigatinib After Chemotherapy for the Treatment of Newly Diagnosed Acute Myeloid Leukemia
- OHSU Knight Cancer Institute, Portland
ተሳታዮችን በመፈለግ ላይደረጃ 1
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ14 ጁላይ 2026 · NCT04659616Induction and Consolidation With Fludarabine, Cytarabine, Idarubicin, and Venetoclax for the Treatment of Acute Myeloid Leukemia
- OHSU Knight Cancer Institute, Portland
ተሳታዮችን በመፈለግ ላይደረጃ 2
እድሜ ከ18 እስከ 65 · ሁሉም ጾታዎች · የተሻሻለው በ13 ጁላይ 2026 · NCT07228273Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
- Oregon Health and Science University, Portland
ተሳታዮችን በመፈለግ ላይደረጃ 2
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ7 ጁላይ 2026 · NCT07216443A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
- Oregon Health & Science University/Doernbecher Children's Hospital, Portland
ተሳታዮችን በመፈለግ ላይየመመልከት ጥናት
ለሁሉም እድሜ · ሁሉም ጾታዎች · የተሻሻለው በ6 ጁላይ 2026 · NCT01351545Iadademstat in Combination With Azacitidine and Venetoclax in Treating Newly Diagnosed Acute Myeloid Leukemia
- OHSU Knight Cancer Institute, Portland
ተሳታዮችን በመፈለግ ላይደረጃ 1
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ30 ጁን 2026 · NCT06357182A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
- Oregon Health and Science University, Portland
- Oregon Oncology Specialists, Salem
ተሳታዮችን በመፈለግ ላይደረጃ 2/3
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ30 ኤፕሪ 2026 · NCT04256317A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
- Oncology Associates of Oregon, Eugene
ተሳታዮችን በመፈለግ ላይደረጃ 1/2
እድሜ 12 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ24 ማርች 2026 · NCT04988555A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
- Oregon Health & Science University, Portland
ተሳታዮችን በመፈለግ ላይደረጃ 2
እድሜ ከ18 እስከ 66 · ሁሉም ጾታዎች · የተሻሻለው በ17 ማርች 2026 · NCT06859424A Phase 1 Study of STX-0712 in Patients With Advanced Hematological Malignancies (CMML and AML)
- OHSU, Portland
ተሳታዮችን በመፈለግ ላይደረጃ 1
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ9 ፌብሩ 2026 · NCT06950034Specialty Compared to Oncology Delivered Palliative Care for Patients With Acute Myeloid Leukemia
- Oregon Health & Science University, Portland
ተሳታዮችን በመፈለግ ላይጤናማ ተሳታዮች ይቀበላሉ
እድሜ ከ18 እስከ 120 · ሁሉም ጾታዎች · የተሻሻለው በ25 ጁላይ 2025 · NCT05237258ከ ClinicalTrials.gov የተገኘ መረጃ፣ በ6 ኦክቶ 2026 የተሰብሰቡ። እያንዳንዱ ጥናት የራሱን ቅድመ ሁኔታ ይወስናል፤ የጥናት ቡድኑ ማን መሳተፍ እንደሚችል ይወስናል።